Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | ||||||
{[ item.p_purity ]} | {[ item.pr_size ]} | Inquiry |
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price) ]} |
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price) ]} | {[ item.pr_usastock ]} | in stock Inquiry - | {[ item.pr_chinastock ]} | {[ item.pr_remark ]} in stock Inquiry - | Login | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
William F. Tracy ; Geraint H. M. Davies ; Lauren N. Grant , et al. JOC,2024,89(7):4595-4606. DOI: 10.1021/acs.joc.3c02873
More
Abstract: Immunomodulatory imide drugs form the core of many pharmaceutically relevant structures, but Csp2–Csp2 bond formation via metal-catalyzed cross coupling is difficult due to the sensitivity of the glutarimide ring ubiquitous in these structures. We report that replacement of the traditional alkali base with a fluoride source enhances a previously challenging Suzuki–Miyaura coupling on glutarimide-containing compounds with trifluoroborates. These enabling conditions are reactive enough to generate these derivatives in high yields but mild enough to preserve both the glutarimide and its sensitive stereocenter. Experimental and computational data suggest a mechanistically distinct process of π-coordination of the trifluoroborate enabled by these conditions.
Purchased from AmBeed: 395083-14-4 ; 13472-85-0 ; 2093387-36-9 ; 2093536-12-8 ; 2527-99-3 ; 1010100-26-1 ; 2304513-76-4 ; 20493-60-1 ; 2229976-08-1 ; 153766-81-5 ; 15803-02-8 ; 2509137-01-1 ; 233664-53-4 ; 1334497-00-5 ; 34259-99-9 ; 131274-22-1 ; 92629-11-3 ; 906674-55-3 ; 13682-77-4 ; 1111732-84-3 ; 1902198-18-8 ; 30318-99-1 ; 166328-14-9 ; 26166-92-7 ; 835616-62-1 ; 1216805-49-0 ; 24674-39-3 ; 1258323-45-3 ; 1111732-99-0 ; 1186667-20-8 ...More
CAS No. : | 92629-11-3 | MDL No. : | MFCD00466256 |
Formula : | C9H6BrNO | Boiling Point : | No data available |
Linear Structure Formula : | - | InChI Key : | MSXVETKZQOUBNB-UHFFFAOYSA-N |
M.W : | 224.05 | Pubchem ID : | 2773271 |
Synonyms : |
|
Signal Word: | Warning | Class: | |
Precautionary Statements: | P261-P280-P305+P351+P338 | UN#: | |
Hazard Statements: | H302-H315-H319-H332-H335 | Packing Group: | |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
[ 885466-67-1 ]
(4-(Oxazol-2-yl)phenyl)methanamine
Similarity: 0.80
[ 106833-79-8 ]
2-Phenyloxazole-5-carboxylic acid
Similarity: 0.67
[ 760207-87-2 ]
5-Bromo-2-methoxy-3-methylpyridine
Similarity: 0.63
[ 885466-67-1 ]
(4-(Oxazol-2-yl)phenyl)methanamine
Similarity: 0.80
[ 106833-79-8 ]
2-Phenyloxazole-5-carboxylic acid
Similarity: 0.67